ReviewFrontiers in immunology2022
From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases?
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Granulomatous interstitial nephritis due to sarcoidosis following SARS-CoV-2 infection: a rare case report.CEN case reports · 2025Article
- Investigating Metabolic Phenotypes for Sarcoidosis Diagnosis and Exploring Immunometabolic Profiles to Unravel Disease Mechanisms.Metabolites · 2024Article
- New-onset sarcoidosis in a patient with long COVID.Clinical case reports · 2024Article
- Incidence, management and prognosis of new-onset sarcoidosis post COVID-19 infection.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Sarcoidosis detected after COVID‑19 with T‑SPOT.TB positive: A case report.Experimental and therapeutic medicine · 2024Article
- Infectious Complications of Pulmonary Sarcoidosis.Journal of clinical medicine · 2024Review
- Sarcoidosis following COVID infection: A case series.Respirology case reports · 2023Article
- Circulating Regulatory T Cell Subsets in Patients with Sarcoidosis.Diagnostics (Basel, Switzerland) · 2023Article
- Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients.Frontiers in medicine · 2023Review
- Sarcoidosis and autoimmunity: In the depth of a complex relationship.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to the dysregulation of the immune system, exacerbates inflammatory responses, and even causes multiple organ dysfunction syndrome in patients with severe disease. Sarcoidosis is an idiopathic granulomatous multisystem disease characterized by dense epithelioid non-necrotizing lesions with varying degrees of lymphocytic inflammation. These two diseases have similar clinical manifestations and may also influence each other and affect their clinical courses. In this study, we analyzed some possible connections between sarcoidosis and COVID-19, including the role of the renin-angiotensin system in the respiratory system, immune response, and cell death pathways, to understand the underlying mechanisms of SARS-CoV-2 infection, predisposing patients to severe forms of COVID-19. This review will provide a new prospect for the treatment of COVID-19 and an opportunity to explore the pathogenesis and development of sarcoidosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.